Trials / Active Not Recruiting
Active Not RecruitingNCT06683742
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- Sponsor
- EyePoint Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EYP-1901 | Intravitreal Injection |
| DRUG | Aflibercept (2.0 mg) | Intravitreal Injection |
Timeline
- Start date
- 2024-11-27
- Primary completion
- 2026-10-01
- Completion
- 2027-10-01
- First posted
- 2024-11-12
- Last updated
- 2026-04-02
Locations
129 sites across 10 countries: United States, Brazil, Czechia, Germany, Hungary, India, Israel, Poland, Slovakia, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06683742. Inclusion in this directory is not an endorsement.